Search

Microarray technology, recently implemented in international prenatal diagnosis systems, has become one of the main techniques in this field in terms of detection rate and objectivity of the results. This guideline attempts to provide background information on this technology, including technical and diagnostic aspects to be considered. Specifically, this guideline defines: the different prenatal sample types to be used, as well as their characteristics (chorionic villi samples, amniotic fluid, fetal cord blood or miscarriage tissue material); variant reporting policies (including variants of uncertain significance) to be considered in informed consents and prenatal microarray reports; microarray limitations inherent to the technique and which must be taken into account when recommending microarray testing for diagnosis; a detailed clinical algorithm recommending the use of microarray testing and its introduction into routine clinical practice within the context of other genetic tests, including pregnancies in families with a genetic history or specific syndrome suspicion, first trimester increased nuchal translucency or second trimester heart malformation and ultrasound findings not related to a known or specific syndrome. This guideline has been coordinated by the Spanish Association for Prenatal Diagnosis (AEDP, «Asociación Española de Diagnóstico Prenatal»), the Spanish Human Genetics Association (AEGH, «Asociación Española de Genética Humana») and the Spanish Society of Clinical Genetics and Dysmorphology (SEGCyD, «Sociedad Española de Genética Clínica y Dismorfología»)., (Copyright © 2017 Elsevier España, S.L.U. All rights reserved.)

Unlabelled: FUNDAMENTAL AND OBJECTIVE: Holt-Oram syndrome (HOS) is a heart-hand disease with an autosomal dominant inheritance pattern. About 85% of the affected patients present de novo mutations in the TBX5 gene. The aim of this study is to propose a molecular strategy to diagnose patients with clinical suspicion of HOS., Patients and Methods: A sequence analysis of 7 patients from exon 2 to exon 8 of the TBX5 gene was performed. MLPAp179 and MLPAp180 were performed in those cases in which no mutation was found., Results: p.Arg270X and p.Ala34Glyfsx27 mutations were identified in 2 cases. These cases fulfilled the strict clinical criteria, had a family history of HOS and had similar clinical features. In other three cases, MLPA results showed deletions of the GLI3 coding region., Conclusions: In order to increase the TBX5 mutation detection rate, an exhaustive physical examination focused on the strict clinical criteria may be necessary to rule out clinical overlapping syndromes. We propose that molecular analysis of GLI3 may be performed in patients with clinical suspicion of HOS without mutations in TBX5., (Copyright © 2010 Elsevier España, S.L. All rights reserved.)